Physician profile
Patrick T Fox
NPI 1780846295
$2,784.96
in general payments reported to CMS, 2019-2025
20 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.71 · 2023: $415 · 2024: $1,062 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.15 | 2023-2025 | |
| Lilly USA, LLC | $428.33 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $309.90 | 2023-2025 | |
| Novo Nordisk INC | $227.25 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $161.72 | 2023-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.11 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $115.60 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $102.28 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Neurocrine Biosciences, INC. | $72.99 | 2024-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $64.79 | 2024-2025 | Xtampza, Belbuca |
| Exact Sciences Corporation | $63.80 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $35.03 | 2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.46 | 2025 | Caplyta |
| Abiomed | $32.11 | 2024 | Impella |
| Medtronic, INC. | $25.85 | 2023 | Signia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.44 | 2024 | |
| Seqirus USA INC | $23.28 | 2025 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $18.92 | 2023 | Trintellix |
| Edwards Lifesciences Corporation | $15.35 | 2025 | Sapien 3 Ultra Resilia |
| Phathom Pharmaceuticals, INC. | $3.60 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.